Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changfa Xia

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The Lancet. Global Health|January 27, 2019
Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessmentWanqing Chen, Changfa Xia, Rongshou Zheng, et al.
Translational Lung Cancer Research|September 12, 2022
Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in ChinaSiyi He, He Li, Maomao Cao, et al.
Cancer|August 23, 2022
Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high-risk population: A cross-sectional studyMaomao Cao, He Li, Dianqin Sun, et al.
JAMA Network Open|December 19, 2022
Long-term Incidence Rates of Esophageal Squamous Cell Carcinoma in Chinese Patients With Low-grade Intraepithelial Neoplasia and Association of Surveillance Endoscopy With IncidenceHe Li, Hongliang Wu, Maomao Cao, et al.
Science China. Life Sciences|September 10, 2024
Can patients with mild non-neoplastic lesions diagnosed at baseline screening be safely exempt from surveillance: evidence from multicenter community-based cohortsSiyi He, Zhiyi Zhang, Guohui Song, et al.
Chinese Medical Journal|April 1, 2026
Management and outcomes of patients with liver cancer in China and the United StatesMengyuan Xu, Qiushuo Geng, Tianhao Shan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 20, 2022
Risk-Adapted Starting Age for Personalized Colorectal Cancer Screening: Validated Evidence From National Population-Based StudiesXuesi Dong, Zilin Luo, Zheng Wu, et al.
Future Oncology (London, England)|January 5, 2024
Multicenter phase II study of moderate low-dose radiotherapy in indolent non-Hodgkin lymphoma: CLCG-iNHL-01 protocolLin-Rui Gao, Xinyue Wang, Changfa Xia, et al.
Plos Medicine|February 22, 2024
Combining fecal immunochemical testing and questionnaire-based risk assessment in selecting participants for colonoscopy screening in the Chinese National Colorectal Cancer Screening Programs: A population-based cohort studyXuesi Dong, Lingbin Du, Zilin Luo, et al.
Science Bulletin|January 21, 2026
Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022Ping Li, Zhan Ding, Yuqi Feng, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The Lancet. Global Health|January 27, 2019
Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessmentWanqing Chen, Changfa Xia, Rongshou Zheng, et al.
Translational Lung Cancer Research|September 12, 2022
Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in ChinaSiyi He, He Li, Maomao Cao, et al.
Cancer|August 23, 2022
Assessment of the compliance, influencing factors, and yielding results of liver cancer screening in a high-risk population: A cross-sectional studyMaomao Cao, He Li, Dianqin Sun, et al.
JAMA Network Open|December 19, 2022
Long-term Incidence Rates of Esophageal Squamous Cell Carcinoma in Chinese Patients With Low-grade Intraepithelial Neoplasia and Association of Surveillance Endoscopy With IncidenceHe Li, Hongliang Wu, Maomao Cao, et al.
Science China. Life Sciences|September 10, 2024
Can patients with mild non-neoplastic lesions diagnosed at baseline screening be safely exempt from surveillance: evidence from multicenter community-based cohortsSiyi He, Zhiyi Zhang, Guohui Song, et al.
Chinese Medical Journal|April 1, 2026
Management and outcomes of patients with liver cancer in China and the United StatesMengyuan Xu, Qiushuo Geng, Tianhao Shan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 20, 2022
Risk-Adapted Starting Age for Personalized Colorectal Cancer Screening: Validated Evidence From National Population-Based StudiesXuesi Dong, Zilin Luo, Zheng Wu, et al.
Future Oncology (London, England)|January 5, 2024
Multicenter phase II study of moderate low-dose radiotherapy in indolent non-Hodgkin lymphoma: CLCG-iNHL-01 protocolLin-Rui Gao, Xinyue Wang, Changfa Xia, et al.
Plos Medicine|February 22, 2024
Combining fecal immunochemical testing and questionnaire-based risk assessment in selecting participants for colonoscopy screening in the Chinese National Colorectal Cancer Screening Programs: A population-based cohort studyXuesi Dong, Lingbin Du, Zilin Luo, et al.
Science Bulletin|January 21, 2026
Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022Ping Li, Zhan Ding, Yuqi Feng, et al.
Pageof 10